Erdmute / DERMAGO

Bildschirmfoto-2023-04-26-um-12.19.44-1200x540.jpg

26. April 2023 Press0


Today Skin Care Pharma GmbH announces the successful submission of the Marketing Authorisation application of its product Skinatan® cream, the first generic version of the originator product Advantan® (active substance: Methlyprednisolone aceponate) to the South African competent local authority SAHPRA (“South African Health Products Regulatory Authority“). Submission was made successfully under the responsibility of Abex Pharmaceutica (Pty) Ltd., the commercial partner of Skin Care Pharma in South Africa and Australia.

Skin Care Pharma and Abex Pharmaceutica entered into a mutually exclusive partnership Agreement for the registration and commercialization of Skinatan® formulations in South Africa and Australia in 2020.

After the submission of the Skinatan® Cream Marketing Authorisation Applications in certain European countries, South Africa is the first country outside of Europe, where the cream formulation has been presented to the regulatory authorities for assessment of approvability.  

Ed Hallam, Chief Executive Officer of Abex comments: “Once Abex has been granted approval for the Skinatan® product range, it will create an opportunity for us to bring a new high quality cost effective generic option into the hands of health care practitioners, this will increase access and improve the quality of lives of South African patients living with eczema. South Africa represents a growing market where the prevalence of atopic dermatitis ranges from between 4.7% of the adult population to approximately 23% in children who suffer from this skin condition. This opportunity is fully in line with our objectives to strengthen key therapeutic areas, and we are looking forward to expanding our partnership with Skin Care Pharma with exciting new projects.”

Sven Schimansky-Wabra, Chief Executive Officer of Skin Care Pharma adds: “Congratulations to the whole Abex team for achievement of this important milestone in South Africa. The ongoing submission process in South Africa starts a series of registrations for Skinatan® in further countries in the coming months.“

About Abex:

Abex Pharmaceutica (Pty) Ltd is a South African-based international healthcare company involved in the development, manufacturing, registration, and commercialisation of prescription and over-the-counter pharmaceuticals which have been clinically proven to meet international standards. The company is recognised globally for its networks and excellence in service, reliability, high quality, effective and innovative healthcare solutions. Abex is a privately owned, family business, with headquarters and operational focus in South Africa; as well as international B2B operations in the United Kingdom, Australia, New Zealand, China and selected countries across MENA and LATAM geographies.  

About Skin Care Pharma, part of the DERMAGO Group:

Skin Care Pharma GmbH is part of the DERMAGO Group, with headquarters in Strausberg, Germany.

DERMAGO is a service company that has been specializing in the development of unique generic versions and originator preparations of prescription, reimbursable dermatological pharmaceuticals and in independently advancing these through the pharmaceutical approval process. The services of DERMAGO also include consulting activities, scientific assessments, the preparation of expert reports as well as qualitative and quantitative studies especially for dermatological pharmaceuticals. The development of analytical methods and procedures as well as services for obtaining marketing authorization for pharmaceutical products are also part of the range of the company’s activities.


SvenSchimansky_StefanieRichter-1-1200x1066.jpg

20. April 2023 Press0

Since April, Stefanie Richter has joined the company’s management team. Together with Sven Schimansky-Wabra, they will set sail for the future.

Strausberg, April 19th, 2023.

DERMAGO GmbH announced today the strengthening of its management team and the addition of experienced financial expert Stefanie Richter.
Additional services through the laboratory, sharpened strategic alignment: DERMAGO GmbH is on a growth trajectory and has brought additional expertise on board. With Stefanie Richter and Sven Schimansky-Wabra, two managing directors now jointly lead the fortunes of the DERMAGO Group.
Sven Schimansky-Wabra says: “The entire DERMAGO team warmly welcomes Stefanie Richter. After planning our new laboratory in Strausberg and applying for approval from the state authority, we want to continue growing with new projects. Stefanie will lead us with her many years of expertise in the financial sector in aligning and financing our growth strategy.”

In the future, Sven Schimansky-Wabra will be responsible for strategy, operational planning, product development, and laboratory services. His new partner, Stefanie Richter, will take over finance, controlling, personnel, and administration.

Stefanie Richter has gained her high level of professional experience in many positions and brings more than 15 years of experience in finance & controlling as well as personnel management. Most recently, she was responsible for the commercial management of a medium-sized company in Brandenburg.

Stefanie Richter explains the change: “DERMAGO has steadily grown and developed very well in recent years. Now, the next steps in development are ahead. I am excited to be part of this future.”

The DERMAGO Group includes:
Skin Care Pharma GmbH with Skinatan® as the first generic approval for Advantan®, a prescription drug for the indications of atopic dermatitis and psoriasis in individual countries.
DEGODE Pharma GmbH with Beloren® as the first generic development for the prescription originator product Skinoren/Finacea, approved for acne/rosacea indications.
As well as:
Aresus Pharma GmbH with Veregen®, a patented, prescription-only original product approved for the indication of condylomata acuminata caused by HPV viruses.



29. June 2022 Press0

DERMAGO receives 2 million euros by private investor network.

Via Companisto, more than 750 private investors participate in the financing of the pharmaceutical company with international sales and distribution.

Berlin, 28 June 2022

In the financing round on Companisto, the pharmaceutical company DERMAGO GmbH received an investment commitment of just under 2 million euros within only a few weeks. More than 750 private investors participated in the pharmaceutical company, which has already launched 2 out of 3 reimbursable pharmaceuticals for international distribution on the market.

The pharmaceutical company has been developing and marketing generics for prescription medicines in the field of skin diseases. In addition, the company also has a patent-protected originator product in the same field.

By investing in DERMAGO GmbH, the investors had the opportunity to make investments in three pharmaceutical companies at the same time with DERMAGO GmbH acting as the parent company of its subsidiaries Aresus Pharma, DEGODE Pharma and Skin Care Pharma. Both DEGODE Pharma and Aresus Pharma are no strangers to the private investor network.

Already in 2018, DEGODE Pharma completed a successful financing round on Companisto. In 2019, Aresus Pharma followed suit and was also able to successfully complete the round.

In 2021, the parent company was founded to create synergy effects in the areas of distribution, administration, development as well as quality management and was carried out with the support of Companisto. The funds from the current financing round are to be used both for sales expansion and for the clinical study of a new indication.

Owing to the investment round on Companisto, the pharmaceutical company was also able to gain additional active supporters for the further development of the startup.

Along with many other relevant industries, investors from the health care and pharmaceutical industries can be found in the Companisto private investor network, who are supporting DERMAGO in its further growth.

Press release – Companisto – DERMAGO GmbH financing round

COMPANISTO

Sven Schimansky-Wabra, founder and general manager of DERMAGO GmbH, commented on the successfully completed financing round on Companisto: “I am really pleased that we have completed another successful financing round with Companisto and would like to thank our investors for the trust they have vested in us.

We will make good use of the funds to advance the clinical development of our products and provide patients and physicians with new treatment options”.

About DERMAGO

DERMAGO GmbH is a service company that has been specializing in the development of unique generic versions and originator preparations of prescription, reimbursable dermatological pharmaceuticals and in independently advancing these through the pharmaceutical approval process.

The services of DERMAGO GmbH also include consulting activities, scientific assessments, the preparation of expert reports as well as qualitative and quantitative studies especially for dermatological pharmaceuticals.

The development of analytical methods and procedures as well as services for obtaining marketing authorization for pharmaceutical products are also part of the range of the company’s activities.

About Companisto

Companisto is the market-leading private investor network in the D-A-CH region (Germany, Austria and Switzerland) and has been the most active private venture capital provider in Germany for five years in a row.

Over 152 million euros have been committed via Companisto to date in currently 230 financing rounds. Since 2018, Companisto has expanded its network of at present 124,000 private investors with a digitally organized Business Angel Club. Some 1,400 business angels invest in the equity of companies via Companisto with investments starting at 10,000 euros.

The investment process and management of participations have been fully digitalized.

Further information

www.companisto.com, www.companisto.com/de/angel-club, www.dermago-group.com

Contact partner

presse@companisto.com

Companisto GmbH | Köpenicker Str. 154 | 10997 Berlin

 

 

Press release – Companisto – DERMAGO GmbH financing round